# ğŸ­ Industry Scorecard â€“ India (June 2025)

*(1 â­ = very unfavourable, 5 â­ = very favourable for equity returns over the next 2â€‘3 years)*

| Industry                          | Structural Tailwinds | Govt & Policy Support | Margin Expansion | Capital Efficiency | Valuation & Sentiment | **Overall**     |
|-----------------------------------|-----------------------|------------------------|------------------|---------------------|------------------------|------------------|
| **Renewable Energy & Green Hydrogen** | â­â­â­â­â­<br>Decarbonisation + netâ€‘zero targets | â­â­â­â­â­ National Green Hydrogen Mission, higher budget outlays | â­â­â­ Supply-chain scale-up still volatile | â­â­â­ Cap-heavy but long-life assets | â­â­â­ Rich multiples but broad FII interest | **â­ â­ â­ â­ (4/5)** |
| **Electric Vehicles & Batteries** | â­â­â­â­ 4% car share and rising | â­â­â­â­â­ FAME II + PLI, duty cuts | â­â­â­ OEM pricing power limited | â­â­â­ Big capex for cells & packs | â­â­ Valuations lofty; hype risk | **â­ â­ â­ (3/5)** |
| **Information Technology / Digital Services** | â­â­â­â­ Global digital + AI spend | â­â­â­ SEZ/ tax perks steady | â­â­â­â­ Automation lifts EBIT margins | â­â­â­â­â­ Asset-light; ROE > 25% | â­â­â­ Nifty IT P/E â‰ˆ 28Ã— | **â­ â­ â­ â­ (4/5)** |
| **Pharmaceuticals & Biotech**     | â­â­â­â­ Generic exports + health spend | â­â­â­â­ Bulk-drug & vaccine PLIs | â­â­â­ Pricing pressure abroad | â­â­â­â­ ROCE mid-teens to 20% | â­â­â­ Fair multiples | **â­ â­ â­ â­ (4/5)** |
| **Banking & Financial Services**  | â­â­â­â­ Credit growth, lower NPAs | â­â­â­ Stable regulation | â­â­â­ NIMs may compress with rate cuts | â­â­â­â­ ROE â‰ˆ 14â€“15% | â­â­â­â­ Valuations still below 10-yr avg; strong FII/DII flows | **â­ â­ â­ â­ (4/5)** |
| **Consumer Staples / FMCG**       | â­â­â­â­ Rising rural demand | â­â­â­ PLI for food processing | â­â­â­â­ Soft commodities aid margins | â­â­â­â­â­ High cash-gen / asset-light | â­â­ Expensive P/E 35â€“45Ã— | **â­ â­ â­ â­ (4/5)** |
| **Specialty Chemicals**           | â­â­â­â­â­ China+1 export boom | â­â­â­â­ PLI + Make-in-India push | â­â­â­â­ Niche pricing power | â­â­â­â­ Sector ROCE often 20â€“40% | â­â­ Premium valuations after 2021 rally | **â­ â­ â­ â­ (4/5)** |
| **Capital Goods & Defence Infra** | â­â­â­â­ Capex super-cycle | â­â­â­â­â­ Record infra & defence orders | â­â­â­â­ Operating-leverage tailwind | â­â­â­ Improving ROCE (12 â†’ 22%) | â­â­â­ Healthy FII appetite | **â­ â­ â­ â­ (4/5)** |

---

## ğŸ… Top Five Industries to Watch (2025â€“27)

1. **Renewable Energy & Green Hydrogen** â€“ policy rocket fuel plus secular demand.  
2. **Specialty Chemicals** â€“ China+1 and high ROCE offer structural upside.  
3. **Capital Goods & Defence** â€“ capex pipeline translating into earnings leverage.  
4. **Information Technology** â€“ asset-light, cash-rich, poised to monetise AI services.  
5. **Banking & Financials** â€“ cleaned balance sheets, accelerating credit, attractive valuations.

*(Pharma and FMCG remain solid defensives but may deliver steadier, moderate returns.)*

---

## ğŸ’¡ Investor Takeaway

> â€œMacro tailwinds, supportive policy, and solid capital efficiency are converging in renewables, specialty chemicals, cap-goods, IT, and banking. Keep valuations and execution risks in view, but these five sectors look best-placed to compound over the next 2â€“3 years.â€
